Eli Lilly reported top-line results from Transcend‑T2D‑1 showing retatrutide, a GIP/GLP‑1/glucagon triple agonist, produced up to a 2.0 percentage‑point A1C reduction and mean weight loss of 36.6 pounds at 40 weeks. The company said the drug met the trial’s primary and all key secondary endpoints; safety signals mirrored those seen with incretin therapies, including gastrointestinal effects. The lead finding advances a next‑generation metabolic class that targets three hormone receptors simultaneously to combine glycemic control with enhanced weight loss. Clinicians caution that full peer‑reviewed data and longer follow‑up will be needed to assess durability and rare adverse events.